Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, UCSF Ink Cell Line Collaboration

NEW YORK (GenomeWeb News) – Sigma-Aldrich announced today that it has entered into a five-year deal with the University of California, San Francisco, to develop optimal cell lines for the production of monoclonal antibodies.
UCSF researchers will use the cell lines conduct the research into antibodies for a variety of cancer targets, autoimmune diseases, stem cell characteristics, and commonly neglected disease targets. The university will have free access to antibodies resulting from the partnership for its ongoing immunology and disease research, Sigma-Aldrich said.
Further terms of the alliance were not disclosed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.